• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Echo Therapeutics

edit

Echo Therapeutics (OTCBB: ECTE) is developing its Symphony tCGM System, a novel, non-invasive (needle-free), wireless, transdermal continuous transdermal glucose monitoring (tCGM) system for people with diabetes and for use in hospital critical care units, and a pipeline of specialty pharmaceutical products incorporating its proprietary AzoneTS transdermal drug reformulation technology.

Echo is leveraging its unique, long-term strategic development relationship with Cato Research, a global contract research and development organization (CRO) and an affiliate of Echo’s largest institutional investor, Cato BioVentures, to develop its pharmaceutical pipeline efficiently and cost-effectively.

Recent Milestones

edit

• 
  Echo Therapeutics received $5.5M in Venture Round funding. (1/6/11)
  Posted 1/17/11 at 3:38am via masshightech.com
• 
  Echo Therapeutics received $563k in Venture Round funding. (12/3/09)
  Posted 12/7/09 at 3:12pm via sec.gov
• 
  Echo Therapeutics received $3M in Venture Round funding. (11/13/09)
  Posted 11/13/09 at 2:26pm via masshightech.com
• 
  Echo Therapeutics received $2M in Angel funding. (7/29/09)
  Posted 11/13/09 at 2:26pm via masshightech.com
• 
  Echo Therapeutics added Patrick Mooney as CEO, President, Chairman. (9/1/07)
  Posted 11/13/09 at 2:26pm
• 
  Echo Therapeutics added Harry Mitchell as COO, CFO.
  Posted 11/13/09 at 2:26pm

Videos

Screenshots

edit

Above: Home Page
Uploaded: 3/13/10

Sources

1. Mass High Tech (masshightech.com) [edit]
2. Mass High Tech (masshightech.com) [edit]
3. SEC D (sec.gov) [edit]
4. Echo Therapeutics calls on $5.5M in new funding (masshightech.com) [edit]